SI9420048B - Farmacevtske formulacije živčnega rastnega faktorja - Google Patents
Farmacevtske formulacije živčnega rastnega faktorja Download PDFInfo
- Publication number
- SI9420048B SI9420048B SI9420048A SI9420048A SI9420048B SI 9420048 B SI9420048 B SI 9420048B SI 9420048 A SI9420048 A SI 9420048A SI 9420048 A SI9420048 A SI 9420048A SI 9420048 B SI9420048 B SI 9420048B
- Authority
- SI
- Slovenia
- Prior art keywords
- formulation
- water
- growth factor
- aqueous
- nerve growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/109,798 US6277828B1 (en) | 1993-08-20 | 1993-08-20 | Pharmaceutical formulations of nerve growth factor |
PCT/US1994/009245 WO1995005845A1 (en) | 1993-08-20 | 1994-08-16 | Pharmaceutical formulations of nerve growth factor |
Publications (2)
Publication Number | Publication Date |
---|---|
SI9420048A SI9420048A (en) | 1996-10-31 |
SI9420048B true SI9420048B (sl) | 2003-12-31 |
Family
ID=22329623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9420048A SI9420048B (sl) | 1993-08-20 | 1994-08-16 | Farmacevtske formulacije živčnega rastnega faktorja |
Country Status (32)
Country | Link |
---|---|
US (2) | US6277828B1 (ro) |
EP (1) | EP0721343B1 (ro) |
JP (2) | JP4592830B2 (ro) |
KR (1) | KR100341193B1 (ro) |
CN (1) | CN1163265C (ro) |
AT (1) | ATE226085T1 (ro) |
AU (1) | AU677699B2 (ro) |
BG (1) | BG62951B1 (ro) |
BR (1) | BR9407278A (ro) |
CA (1) | CA2169834C (ro) |
CZ (1) | CZ292422B6 (ro) |
DE (1) | DE69431562T2 (ro) |
DK (1) | DK0721343T3 (ro) |
ES (1) | ES2181723T3 (ro) |
FI (1) | FI113241B (ro) |
HK (1) | HK1012990A1 (ro) |
HU (1) | HU228152B1 (ro) |
IL (3) | IL124941A (ro) |
LT (1) | LT4051B (ro) |
LV (1) | LV11279B (ro) |
NO (1) | NO317627B1 (ro) |
NZ (1) | NZ271873A (ro) |
PL (1) | PL176387B1 (ro) |
PT (1) | PT721343E (ro) |
RO (1) | RO114742B1 (ro) |
RU (1) | RU2126265C1 (ro) |
SI (1) | SI9420048B (ro) |
SK (1) | SK284064B6 (ro) |
TW (1) | TW427905B (ro) |
UA (1) | UA43348C2 (ro) |
WO (1) | WO1995005845A1 (ro) |
ZA (1) | ZA946333B (ro) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
US6444201B1 (en) * | 1995-05-12 | 2002-09-03 | The Rockefeller University | Treatment of alzheimer disease by modulation of synapsins |
US6090781A (en) * | 1996-11-06 | 2000-07-18 | Genentech, Inc. | Stabilizing formulation for NGF |
ATE255903T1 (de) * | 1995-11-07 | 2003-12-15 | Genentech Inc | Stabilisierende formulierung für ngf |
US6964947B1 (en) | 1995-11-07 | 2005-11-15 | Genentech, Inc. | Stabilizing formulation for NGF |
CA2256333A1 (en) * | 1996-05-29 | 1997-12-04 | Victor Bronshtein | Long-term shelf preservation by vitrification |
CN1059597C (zh) * | 1996-08-08 | 2000-12-20 | 陈素兰 | 神经损伤修复制剂 |
CN1128637C (zh) * | 1997-05-01 | 2003-11-26 | 普罗泰克施恩无限公司 | 作为疫苗佐剂的神经生长因子 |
US6313089B1 (en) | 1997-08-20 | 2001-11-06 | Duke University | Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use |
AU9676598A (en) * | 1997-09-30 | 1999-04-23 | Duke University | Apolipoprotein e/growth factor complexes and methods of use |
US6979442B1 (en) | 1998-08-17 | 2005-12-27 | Pfizer Inc. | Stabilized protein compositions |
AU2002351756A1 (en) | 2001-12-21 | 2003-07-15 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
EP2283856B1 (en) | 2002-06-21 | 2017-09-20 | Novo Nordisk Health Care AG | Stabilised solid compositions of factor VIIa polypeptides |
WO2004082708A2 (en) * | 2003-03-18 | 2004-09-30 | Novo Nordisk Health Care Ag | Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
MXPA05012476A (es) * | 2003-05-23 | 2006-02-22 | Novo Nordisk Healthcare Ag | Estabilizacion de proteina en solucion. |
CN1318087C (zh) * | 2003-06-06 | 2007-05-30 | 北京三诺佳邑生物技术有限责任公司 | 去白蛋白神经生长因子制剂 |
WO2004112828A1 (en) * | 2003-06-25 | 2004-12-29 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
DE602004023848D1 (de) * | 2003-07-01 | 2009-12-10 | Novo Nordisk Healthcare Ag | Von factor vii polypeptiden |
BRPI0413518A (pt) * | 2003-08-14 | 2006-10-10 | Novo Nordisk Healthcare Ag | composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético |
TR201809670T4 (tr) * | 2003-12-19 | 2018-07-23 | Novo Nordisk Healthcare Ag | Faktör VII polipeptitlerinin stabilize edilmiş kompozisyonları. |
US8017151B2 (en) * | 2004-09-07 | 2011-09-13 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Amphiphilic polymer-protein conjugates and methods of use thereof |
US8168222B2 (en) | 2004-09-07 | 2012-05-01 | Board Of Regents Of The University Of Nebraska | Amphiphilic polymer-protein conjugates and methods of use thereof |
WO2008020584A1 (fr) * | 2006-08-14 | 2008-02-21 | Eisai R & D Management Co., Ltd. | Préparation lyophilisée stable |
WO2008056414A1 (fr) * | 2006-11-08 | 2008-05-15 | Medical Appliance Co., Ltd. | Appareil accélérant la production de facteur neurotrophique |
EP1958618A1 (de) | 2007-02-15 | 2008-08-20 | Octapharma AG | Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren |
EP2349338A2 (fr) * | 2008-09-26 | 2011-08-03 | Adocia | Complexe constitue d'un polysaccharide et d'une hpb |
CN102232932B (zh) * | 2010-04-27 | 2013-06-05 | 重庆莱美药业股份有限公司 | 果胶-阿霉素轭合物的冻干制剂及制备方法 |
KR102017905B1 (ko) | 2011-04-07 | 2019-09-03 | 니오베크스 | Ifn 알파 관련 질환을 치료하는 방법 |
WO2013117729A1 (en) * | 2012-02-08 | 2013-08-15 | Institut National De La Recherche Agronomique | Use of beta-nerve growth factor for inducing ovulation in mammals |
ES2882106T3 (es) * | 2015-04-21 | 2021-12-01 | Staidson Beijing Biopharmaceuticals Co Ltd | Composición de factor de crecimiento nervioso y polvo para inyección |
CN108348579B (zh) * | 2015-04-21 | 2021-04-27 | 舒泰神(北京)生物制药股份有限公司 | 神经生长因子组合物及注射粉剂 |
WO2016169455A1 (zh) * | 2015-04-21 | 2016-10-27 | 舒泰神(北京)生物制药股份有限公司 | 神经生长因子组合物和注射粉剂 |
US9868828B2 (en) * | 2015-06-23 | 2018-01-16 | Amolifescience Co., Ltd. | Defined three-dimensional microenvironment for stem cell |
US20200299371A1 (en) | 2016-03-25 | 2020-09-24 | Astellas Pharma Inc. | Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody |
UA123020C2 (uk) * | 2016-06-01 | 2021-02-03 | Сервьє Айпі Юкей Лімітед | Склади поліалкіленоксид-аспарагінази та способи їхнього виготовлення й використання |
CN109260147B (zh) * | 2018-10-15 | 2019-09-13 | 珠海亿胜生物制药有限公司 | 一种用于治疗或预防神经损伤的重组人碱性成纤维细胞生长因子注射剂 |
US11767504B2 (en) | 2020-08-14 | 2023-09-26 | Albcura Corporation | Albumin compositions and methods of producing and using same |
IL302317A (en) | 2020-10-28 | 2023-06-01 | Dompe Farm Spa | Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ235556A (en) | 1986-11-05 | 1991-06-25 | Ethicon Inc | Breast milk substitute containing recombinant human egf |
NZ226170A (en) * | 1987-09-18 | 1990-07-26 | Ethicon Inc | Stable freeze-dried pharmaceutical composition containing epidermal growth factor |
IT1219874B (it) * | 1988-03-18 | 1990-05-24 | Fidia Farmaceutici | Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche |
US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
JPH0418031A (ja) * | 1989-02-16 | 1992-01-22 | Hiroshi Saito | 損傷治癒促進剤 |
JP3283288B2 (ja) * | 1991-03-08 | 2002-05-20 | 電気化学工業株式会社 | 生理活性ペプチド製剤 |
JP2818834B2 (ja) * | 1991-08-12 | 1998-10-30 | 大塚製薬株式会社 | IL−1α安定化医薬製剤 |
-
1993
- 1993-08-20 US US08/109,798 patent/US6277828B1/en not_active Expired - Lifetime
-
1994
- 1994-08-16 BR BR9407278A patent/BR9407278A/pt not_active Application Discontinuation
- 1994-08-16 PL PL94313084A patent/PL176387B1/pl unknown
- 1994-08-16 UA UA96020622A patent/UA43348C2/uk unknown
- 1994-08-16 EP EP94925903A patent/EP0721343B1/en not_active Expired - Lifetime
- 1994-08-16 HU HU9600371A patent/HU228152B1/hu unknown
- 1994-08-16 RO RO96-00301A patent/RO114742B1/ro unknown
- 1994-08-16 CZ CZ1996424A patent/CZ292422B6/cs not_active IP Right Cessation
- 1994-08-16 DE DE69431562T patent/DE69431562T2/de not_active Expired - Lifetime
- 1994-08-16 JP JP50764495A patent/JP4592830B2/ja not_active Expired - Lifetime
- 1994-08-16 SI SI9420048A patent/SI9420048B/sl unknown
- 1994-08-16 WO PCT/US1994/009245 patent/WO1995005845A1/en active IP Right Grant
- 1994-08-16 RU RU96105951A patent/RU2126265C1/ru active
- 1994-08-16 KR KR1020017005635A patent/KR100341193B1/ko not_active IP Right Cessation
- 1994-08-16 PT PT94925903T patent/PT721343E/pt unknown
- 1994-08-16 ES ES94925903T patent/ES2181723T3/es not_active Expired - Lifetime
- 1994-08-16 CN CNB94193148XA patent/CN1163265C/zh not_active Expired - Lifetime
- 1994-08-16 SK SK183-96A patent/SK284064B6/sk not_active IP Right Cessation
- 1994-08-16 AU AU75668/94A patent/AU677699B2/en not_active Expired
- 1994-08-16 DK DK94925903T patent/DK0721343T3/da active
- 1994-08-16 AT AT94925903T patent/ATE226085T1/de active
- 1994-08-16 CA CA002169834A patent/CA2169834C/en not_active Expired - Lifetime
- 1994-08-16 NZ NZ271873A patent/NZ271873A/en not_active IP Right Cessation
- 1994-08-19 IL IL124941A patent/IL124941A/en not_active IP Right Cessation
- 1994-08-19 ZA ZA946333A patent/ZA946333B/xx unknown
- 1994-08-19 IL IL11072594A patent/IL110725A/en not_active IP Right Cessation
- 1994-08-30 TW TW083107604A patent/TW427905B/zh not_active IP Right Cessation
-
1996
- 1996-02-19 FI FI960750A patent/FI113241B/fi not_active IP Right Cessation
- 1996-02-19 BG BG100371A patent/BG62951B1/bg unknown
- 1996-02-19 NO NO19960651A patent/NO317627B1/no not_active IP Right Cessation
- 1996-02-19 LT LT96-011A patent/LT4051B/lt not_active IP Right Cessation
- 1996-02-19 LV LVP-96-48A patent/LV11279B/en unknown
-
1998
- 1998-06-16 IL IL12494198A patent/IL124941A0/xx active IP Right Grant
- 1998-12-19 HK HK98114132A patent/HK1012990A1/xx not_active IP Right Cessation
-
2001
- 2001-02-20 US US09/789,855 patent/US7074763B2/en not_active Expired - Fee Related
-
2007
- 2007-08-08 JP JP2007206876A patent/JP2007314572A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI9420048B (sl) | Farmacevtske formulacije živčnega rastnega faktorja | |
RU96105951A (ru) | Фармацевтические композиции с фактором роста нерва | |
DE69532970T3 (de) | Sprühgetrocknetes erythropoietin | |
US5456922A (en) | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone | |
US4847079A (en) | Biologically stable interferon compositions comprising thimerosal | |
US4824938A (en) | Water-soluble dry solid containing proteinaceous bioactive substance | |
RU99118890A (ru) | Водорастворимая фармацевтическая композиция в виде ионного комплекса и ее применение | |
CA2019466C (en) | Minerals in bioavailable form | |
KR890003400A (ko) | 경비(經鼻)투여용 생리 활성 펩티드 분말 조성물(제제) | |
KR950702834A (ko) | 글루칸 제제(novel glucan preparation) | |
JP2001010960A (ja) | 局所用亜鉛組成物および使用方法 | |
CA2329000A1 (en) | Stabilised virus preparation | |
KR960700062A (ko) | 산성 pH에서의 안정성을 개선시키기 위해 변형된 올리고누클레오티드(OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACIC pH) | |
DE60028152T2 (de) | Fester, stabiler und konzentrierter biologisch verdaulicher Komplex von Orthokieselsäure und Prozess zur dessen Herstellung | |
CA1115206A (en) | Method for preparing urokinase injection | |
JP2002544241A (ja) | 生体活性剤の改良された細胞取り込み | |
DE04007657T1 (de) | Pharmazeutische Zusammensetzung aus fibrinolytischem Mittel | |
JPS6326120B2 (ro) | ||
JP2000063283A (ja) | ヘッジホッグ蛋白質の薬学的組成物およびその使用 | |
CA2121345A1 (en) | Lipophilic Oligosaccharide Antibiotic Salt Compositions | |
DE69925820T2 (de) | Zubereitungen zur stabilisierung von peg-interferon alpha konjugaten | |
CA2122058A1 (en) | Tgf-beta to improve neural outcome | |
US3940480A (en) | Process for production of stabilized powdery secretin preparation by lyophilization | |
EP1450825B1 (de) | Verwendung von selenithältigen verbindungen zur topischen oder bukkalen anwendung | |
NZ516507A (en) | Growth hormone formulations that are resistant to crystallisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date |